Strategy and Solutions
The client is a seed-stage digital therapeutics startup focused on crisis stabilization and mental health intervention. The organization aimed to develop an FDA-cleared cognitive behavioral therapy (CBT) application integrated with biofeedback capabilities. With limited internal engineering resources and strict regulatory requirements, the startup partnered with Zymr to accelerate product development and validation.
The startup needed to build a Software as a Medical Device (SaMD) platform that met stringent FDA compliance standards while delivering effective, clinically validated CBT interventions. Developing biofeedback-driven therapy protocols required seamless integration of real-time physiological data with therapeutic workflows.
Limited in-house expertise in regulatory-compliant architecture, clinical validation, and interoperability slowed product development. The absence of a scalable clinician interface and lack of EHR integration further restricted adoption across healthcare providers.
Additionally, the company needed to demonstrate measurable clinical outcomes to support regulatory approval and investor confidence. Achieving rapid time-to-market while maintaining compliance and accuracy was critical for securing funding and scaling operations.
Zymr enabled the startup to successfully design, develop, and launch a compliant digital therapeutics platform aligned with FDA standards and clinical best practices.
Zymr delivered an end-to-end digital therapeutics platform with integrated compliance, clinical workflows, and scalable architecture.
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)